(Press-News.org) A glass a day of grapefruit juice lets patients derive the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself, according to a new clinical trial. The combination could help patients avoid side effects associated with high doses of the drug and reduce the cost of the medication.
Researchers at the University of Chicago Medicine study the effects that foods can have on the uptake and elimination of drugs used for cancer treatment. In a study published in August in Clinical Cancer Research, they show that eight ounces a day of grapefruit juice can slow the body's metabolism of a drug called sirolimus, which has been approved for transplant patients but may also help many people with cancer.
Patients who drank eight ounces a day of grapefruit juice increased their sirolimus levels by 350 percent. A drug called ketoconazole that also slows drug metabolism increased sirolimus levels by 500 percent.
"Grapefruit juice, and drugs with a similar mechanism, can significantly increase blood levels of many drugs," said study director Ezra Cohen, MD, a cancer specialist at the University of Chicago Medicine, "but this has long been considered an overdose hazard. Instead, we wanted to see if grapefruit juice can be used in a controlled fashion to increase the availability and efficacy of sirolimus."
Grapefruit juice's pharmaceutical prowess stems from its ability to inhibit enzymes in the intestine that break down sirolimus and several other drugs. The effect begins within a few hours of what the researchers refer to as "grapefruit juice administration." It wears off gradually over a few days.
Cohen and colleagues organized three simultaneous phase-1 trials of sirolimus. Patients received only sirolimus, sirolimus plus ketoconazole, or sirolimus plus grapefruit juice. They enrolled 138 patients with incurable cancer and no known effective therapy.
The first patients started with very low sirolimus doses, but the amounts increased as the study went on, to see how much of the drug was required in each setting to reach targeted levels, so that patients got the greatest anti-cancer effect with the least side effects.
The optimal cancer-fighting dose for those taking sirolimus was about 90 mg per week. At doses above 45 mg, however, the drug caused serious gastrointestinal problems, such as nausea and diarrhea, so patients taking sirolimus alone switched to 45 mg twice a week.
The optimal doses for the other two groups were much lower. Patients taking sirolimus plus ketoconazole, needed only 16 mg per week to maintain the same levels of drug in the blood. Those taking sirolimus plus grapefruit juice, needed between 25 and 35 mg of sirolimus per week.
"This is the first cancer study to harness this drug-food interaction," the authors note.
No patients in the study had a complete response, but about 30 percent of patients in the three trials had stable disease, meaning a period when their cancers did not advance. One patient receiving grapefruit juice had a partial response—significant tumor shrinkage—that lasted for more than three years.
Although ketoconazole produced a slightly stronger drug-retention effect, grapefruit juice has the advantage that it is non-toxic, with no risk of overdose. "Therefore," the authors wrote, "we have at our disposal an agent that can markedly increase bioavailability (in this study by approximately 350%) and, critically in the current environment, decrease prescription drug spending on many agents metabolized by P450 enzymes."
Sirolimus was the first of a series of drugs, known as mTOR inhibitors, that were developed to prevent rejection of transplanted organs but that also have anti-cancer effects. As the first of its class, it was also the first to come off patent, making it less costly. "Further cost savings," the authors suggest, could be realized "by combining the drug with agents that inhibit its metabolism."
Because different people produce varied amounts of the enzymes that break down sirolimus, the effect of grapefruit juice can vary, but tests of enzyme levels may be able to predict how an individual patient will respond.
"The variation in potency of the grapefruit juice itself may be far greater than the variation in the enzymes that break down sirolimus," Cohen said. An early version of the study used canned grapefruit juice, generously donated by a Chicago-based grocery chain. But tests of the product found it lacked the active ingredients. So the researchers shifted to a frozen concentrate product supplied by the Florida Department of Citrus.
INFORMATION:
This study was supported by the National Institutes of Health—and not by a pharmaceutical company. Dose-finding studies are "not necessarily profitable" for drug makers, the authors note, especially if the study results in lower recommended doses after the drug has been approved and priced.
Additional authors of this study include Kehua Wu, Christine Hartford, Masha Kocherginsky, Yuanyuan Zha, Anitha Nallari, Michael Maitland, Kammi Fox-Kay, Kristin Moshier, Larry House, Jacqueline Ramirez, Samir Undevia, Gini Fleming, Thomas Gajewski and Mark Ratain of the University of Chicago, and Kimberly Eaton of the University of Texas Medical School at Houston.
A new disinfectant, Akwaton, that works at extremely low concentrations could be used in healthcare settings to help control persistent hospital-acquired infections such as Clostridium difficile. The study is reported online in the Journal of Medical Microbiology.
Researchers from the Université de Saint-Boniface in Winnipeg, Canada tested the new compound, Akwaton, against bacterial spores that attach to surfaces and are difficult to destroy. Previous work by the group has shown Akwaton is also effective at low concentrations against strains of Meticillin-resistant Staphylococcus ...
They say the real crisis stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones.
Since the early 2000s, numerous articles and reports have claimed that the pipeline for new drugs will soon run dry, write Donald Light from the University of Medicine and Dentistry of New Jersey and Joel Lexchin from York University in Toronto. Yet data indicate that the number of new drugs licensed remains at the long term average range of 15-25 a year.
The authors argue that telling "innovation crisis" ...
It has recently been suggested that patients should be kept alive using elective ventilation to facilitate the harvesting of organs for donation. But David Shaw, Honorary Lecturer at the University of Aberdeen believes there is a much simpler way to increase the number of donated organs – by ensuring that doctors respect the wishes of the deceased and over-rule any veto.
Veto by the family is the main impediment to an increase in organ donation, with at least 10% of families refusing to donate. Yet Shaw points out that families have no legal grounds for over-riding the ...
Balance and strength training is known to reduce falls in older adults. However, less than 10% of older people routinely engage in strength training and it is likely that this is much lower for activities that challenge balance.
It has been suggested that integrating exercise into everyday activities may help people stick to it, but this approach has never been investigated in frail older people at risk of falls.
So a team of researchers at the University of Sydney designed and tested the Lifestyle integrated Functional Exercise (LiFE) programme, which involves embedding ...
CORVALLIS, Ore. – A survey of teachers from the United States and Canada found that one out of four educators who used live animals as part of their science curriculum released the organisms into the wild after they were done using them in the classroom.
Yet only 10 percent of those teachers participated in a planned release program, increasing the likelihood that the well-intentioned practice of using live organisms as a teaching tool may be contributing to invasive species problems.
The study was presented today (Aug. 7) in Portland at the national meeting of the ...
New research published online in the scientific journal Addiction shows that plain packaging (requiring cigarettes to be packaged in standard packages without attractive designs and imagery) may help to draw the attention of some adolescent smokers to the health warnings on the package. If so, this may in turn deter young smokers from continuing to smoke.
Researchers asked eighty-seven teenage secondary school (high school) students from the city of Bristol, UK, to look at twenty images of cigarette packs on a computer screen for ten seconds each while a device tracked ...
CHICAGO --- American adults of a normal weight with new-onset diabetes die at a higher rate than overweight/obese adults with the same disease, according to a new Northwestern Medicine study.
The study, to be published in the Aug. 7 issue of JAMA, found that normal-weight participants experienced both significantly higher total and non-cardiovascular mortality than overweight/obese participants.
Normal-weight adults with type 2 diabetes have been understudied because those who typically develop the disease are overweight or obese. In this study about 10 percent of those ...
WINSTON-SALEM, N.C. – August 6, 2012 – When a stroke patient is discharged from the hospital, they often must cope with a new disability or lack of function, so changes in their medications or a new dosing prescription can be particularly confusing. This can lead the patient to overmedicate, take the wrong medication or skip medications entirely and can result in being readmitted to the hospital.
But a pilot study that is looking at a new discharge strategy and being led by researchers at Wake Forest Baptist Medical Center, indicates that phone calls and conversations ...
As the medical community continues to make positive strides in personalized cancer therapy, scientists know some dead ends are unavoidable. Drugs that target specific genes in cancerous cells are effective, but not all proteins are targetable. In fact, it has been estimated that as few as 10 to 15 percent of human proteins are potentially targetable by drugs. For this reason, Georgia Tech researchers are focusing on ways to fight cancer by attacking defective genes before they are able to make proteins.
Professor John McDonald is studying micro RNAs (miRNAs), a class ...
What a University of Central Florida student thought was a failed experiment has led to a serendipitous discovery hailed by some scientists as a potential game changer for the mass production of nanoparticles.
Soroush Shabahang, a graduate student in CREOL (The College of Optics & Photonics), made the finding that could ultimately change the way pharmaceuticals are produced and delivered.
The discovery was based on using heat to break up long, thin fibers into tiny, proportionally sized seeds, which have the capability to hold multiple types of materials locked in ...
